These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 30700368)

  • 1. SGLT-2 Inhibitors: Fighting Cardiovascular Disease Mortality in Diabetes.
    Ghaffar ZA; Anwar S; Rizvi SW
    J Coll Physicians Surg Pak; 2019 Feb; 29(2):195. PubMed ID: 30700368
    [No Abstract]   [Full Text] [Related]  

  • 2. Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors and the Treatment of Type 2 Diabetes.
    Kramer CK; Zinman B
    Annu Rev Med; 2019 Jan; 70():323-334. PubMed ID: 30256723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Class Effect for Sodium Glucose-Cotransporter-2 Inhibitors in Cardiovascular Outcomes: Implications for the Cardiovascular Disease Specialist.
    Bethel MA; McMurray JJV
    Circulation; 2018 Mar; 137(12):1218-1220. PubMed ID: 29555706
    [No Abstract]   [Full Text] [Related]  

  • 4. Cardiovascular benefit in the limelight: shifting type 2 diabetes treatment paradigm towards early combination therapy in patients with overt cardiovascular disease.
    Shehadeh N; Raz I; Nakhleh A
    Cardiovasc Diabetol; 2018 Aug; 17(1):117. PubMed ID: 30134893
    [No Abstract]   [Full Text] [Related]  

  • 5. Differentiating Among the SGLT-2 Inhibitors: Considering Cardiovascular and Other Safety Outcomes.
    Miller EM; Wysham CH
    J Fam Pract; 2018 Aug; 67(8 suppl):S37-S42. PubMed ID: 30137052
    [No Abstract]   [Full Text] [Related]  

  • 6. Are We Ready to Bell The Cat? A Call for Cardiologists to Embrace Glucose-Lowering Therapies Proven to Improve Cardiovascular Outcomes.
    Nassif ME; Kosiborod M
    Circulation; 2018 Jul; 138(1):4-6. PubMed ID: 29967227
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of background insulin therapy on cardiovascular outcomes with SGLT-2 inhibitors in type 2 diabetes: A meta-analysis of cardiovascular outcome trials.
    Singh AK; Singh R
    Diabetes Res Clin Pract; 2021 Feb; 172():108648. PubMed ID: 33421444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiorenal protection of sodium-glucose cotransporter 2 inhibitors beyond diabetes: news from the European Society of Cardiology Congress 2020.
    Ferrannini G
    Eur Heart J Cardiovasc Pharmacother; 2020 Nov; 6(6):341-342. PubMed ID: 32991694
    [No Abstract]   [Full Text] [Related]  

  • 9. Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease.
    Fitchett D; Inzucchi SE; Lachin JM; Wanner C; van de Borne P; Mattheus M; Johansen OE; Woerle HJ; Broedl UC; George JT; Zinman B;
    J Am Coll Cardiol; 2018 Jan; 71(3):364-367. PubMed ID: 29348030
    [No Abstract]   [Full Text] [Related]  

  • 10. Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: A Subanalysis of EMPA-REG OUTCOME.
    Verma S; Mazer CD; Al-Omran M; Inzucchi SE; Fitchett D; Hehnke U; George JT; Zinman B
    Circulation; 2018 Jan; 137(4):405-407. PubMed ID: 29133602
    [No Abstract]   [Full Text] [Related]  

  • 11. SGLT-2 Inhibitors and GLP-1 Agonists: First-Line Therapy for Diabetes With Established Cardiovascular Disease.
    Sajja AP; Dey AK; Guha A; Elnabawi Y; Joshi AA; Kalra A
    J Cardiovasc Pharmacol Ther; 2019 Sep; 24(5):422-427. PubMed ID: 31064213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do the SGLT-2 Inhibitors Offer More than Hypoglycemic Activity?
    Flores E; Santos-Gallego CG; Diaz-Mejía N; Badimon JJ
    Cardiovasc Drugs Ther; 2018 Apr; 32(2):213-222. PubMed ID: 29679303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Update: new forms of therapy for type-2-diabetes].
    Fischli S
    Ther Umsch; 2020 Sep; 77(7):319-327. PubMed ID: 32996424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucose Lowering Strategies for Cardiac Benefits: Pathophysiological Mechanisms.
    Bajaj HS; Zinman B
    Physiology (Bethesda); 2018 May; 33(3):197-210. PubMed ID: 29638185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiometabolic Risk Reduction: A Review of Clinical Guidelines and the Role of SGLT-2 Inhibitors.
    Reid T
    J Fam Pract; 2021 Jul; 70(6S):S1-S6. PubMed ID: 34432617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Introduction.
    Chilton R
    Am J Med; 2017 Jun; 130(6S):S1-S3. PubMed ID: 28526180
    [No Abstract]   [Full Text] [Related]  

  • 17. New anti-diabetic agents: major advances with unanswered questions.
    Sabouret P; Bocchino PP; Biondi-Zoccai G
    Rev Cardiovasc Med; 2020 Dec; 21(4):489-492. PubMed ID: 33387991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dipeptidyl peptidase-4 inhibitor approaches.
    Bloomgarden Z
    J Diabetes; 2017 Jan; 9(1):5-7. PubMed ID: 27576300
    [No Abstract]   [Full Text] [Related]  

  • 19. Cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors in diabetic and nondiabetic patients.
    Xiang B; Zhao X; Zhou X
    Cardiovasc Diabetol; 2021 Apr; 20(1):78. PubMed ID: 33827579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors in patients with type II diabetes mellitus: A meta-analysis of placebo-controlled randomized trials.
    Saad M; Mahmoud AN; Elgendy IY; Abuzaid A; Barakat AF; Elgendy AY; Al-Ani M; Mentias A; Nairooz R; Bavry AA; Mukherjee D
    Int J Cardiol; 2017 Feb; 228():352-358. PubMed ID: 27866027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.